Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer
Phase 1
Terminated
- Conditions
- LeukemiaMyelodysplastic SyndromesMyeloproliferative DisordersLymphoma
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 12
- Registration Number
- NCT00295880
Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine
Not Applicable
Completed
- Conditions
- Ovarian CancerPeritoneal Primary CancerFallopian Tube Cancer
- Interventions
- Drug: Standard chemotherapyOther: healing touchOther: massage therapyOther: hypnosis
- First Posted Date
- 2006-02-17
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 43
- Registration Number
- NCT00293293
- Locations
- πΊπΈ
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer
Not Applicable
Completed
- Conditions
- Chronic Myeloproliferative DisordersLeukemiaMyelodysplastic SyndromesLymphoma
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 68
- Registration Number
- NCT00290641
- Locations
- πΊπΈ
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Not Applicable
Terminated
- Conditions
- Chronic Myeloproliferative DisordersDiamond-blackfan AnemiaFanconi AnemiaGraft Versus Host DiseaseLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 43
- Registration Number
- NCT00290628
- Locations
- πΊπΈ
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ
Phase 2
Terminated
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 45
- Registration Number
- NCT00290654
- Locations
- πΊπΈ
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer
Phase 1
Completed
- Conditions
- Cervical CancerEndometrial CancerFallopian Tube CancerOvarian CancerPeritoneal Cavity CancerSarcomaVaginal CancerVulvar Cancer
- Interventions
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 18
- Registration Number
- NCT00287885
Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Phase 1
Terminated
- Conditions
- Fallopian Tube CancerOvarian CancerPeritoneal Cavity Cancer
- Interventions
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 5
- Registration Number
- NCT00287859
- Locations
- πΊπΈ
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Cervical Cancer
Phase 1
Completed
- Conditions
- Cervical Cancer
- Interventions
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 18
- Registration Number
- NCT00287911
- Locations
- πΊπΈ
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer
Phase 2
Terminated
- Conditions
- Lung Cancer
- Interventions
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 22
- Registration Number
- NCT00281827
- Locations
- πΊπΈ
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
πΊπΈHubert H. Humphrey Cancer Center at North Memorial Outpatient Center, Robbinsdale, Minnesota, United States
πΊπΈNorris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
Phase 2
Terminated
- Conditions
- Hodgkin's LymphomaAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaNon-Hodgkin's LymphomaMultiple MyelomaChronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 6
- Registration Number
- NCT00276159
- Locations
- πΊπΈ
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States